Table 3.
Duloxetine in the treatment of SUI: Results of 3 Phase III efficacy studies, duloxetine 40 mg twice daily
| IEF median reduction | MTBV improvement | I-QOL | PGI-I improvement | Author/study | |
|---|---|---|---|---|---|
| Duloxetine | 50% | 20.0 min | 11.1 | 62% | Dmochowski et al 2003 |
| Placebo | 27.5% | 1.7 min | 6.8 | 39.6% | |
| p | < 0.001 | < 0.001 | < 0.001 | < 0.001 | |
| Duloxetine | 54% | 20.4 min | 10.3 | 74% | Millard et al 2004 |
| Placebo | 40% | 8.5 min | 6.4 | 64% | |
| p | 0.05 | < 0.001 | 0.007 | 0.03 | |
| Duloxetine | 50% | 15.0 min | 5.5 | 56.2% | van Kerrebroeck et al 2004 |
| Placebo | 29.3% | 3.8 min | 4.1 | 48.2% | |
| p | 0.002 | < 0.001 | 0.13 | ns |
Abbreviations: IEF, incontinence episode frequency; I-QOL, Incontinence Quality of Life Questionnaire; MTBV, mean time between voids; min, minimum; ns, not significant; PGI-I, Patient Global Impression-Improvement; SUI, stress urinary incontinence.